Author

Xinghui Chen

Observed name: X. Chen

Observed institutions: Tongji University, Shanghai Pulmonary Hospital, Shanghai Tenth People's Hospital, TYK Medicines, Inc., Inner Mongolia Medical University, Nanjing Medical University

ORCID: 0000-0003-1112-8352

Observed ORCID: 0000-0003-1112-8352

OpenAlex ID: A5102730305

Lobar Torsion after Video-Assisted Thoracoscopic Lobectomy: 2 Case Reports

2011 · L. Duan, X. Chen, et al. · The Thoracic and Cardiovascular Surgeon · 20

Development of a rapid zebrafish model for lead poisoning research and drugs screening

2023 · Shengya Guo, Xiaoxi Zhang, et al. · Chemosphere · 10

P1.01-111 EGFR exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer

2018 · C. Zhao, X. Li, et al. · Journal of Thoracic Oncology · 5

OA05.03 Ablation to Oligo-Residual Sites Plus ICIs Improved Survival of Patients with Advanced NSCLC: Preliminary Results of a Prospective Phase II Trial

2024 · S. Yang, B. Chen, et al. · Journal of Thoracic Oncology · 3

PDF

156P: Correlation of baseline value of folate receptor-positive circulating tumor cells and efficacy of pemetrexed and dynamic monitoring study in NSCLC patients receiving first-line platinum-based chemotherapy

2016 · X. Chen, C. Zhou, et al. · Journal of Thoracic Oncology · 3

PDF

Cutaneous squamous cell carcinoma-derived exosomal MicroRNA-31 acts as an oncogene by targeting the tumor suppressor RhoBTB1

2024 · Yanan Mu, Chen Lian, et al. · Archives of Dermatological Research · 2

P1.01-62 Association of Baseline Pulmonary Fibrosis with the Outcome of PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer

2019 · S. Mao, Y. Liu, et al. · Journal of Thoracic Oncology · 2

JCSE01.26 PD-1 Inhibitor Plus Chemotherapy as 2nd/Subsequent Line Setting Demonstrate Superior Efficacy over PD-1 Inhibitor Alone in Pts of Advanced NSCLC

2019 · S. Ren, Y. Liu, et al. · Journal of Thoracic Oncology · 2

P3.04-21 Antibiotics Attenuate the Clinical Benefit of Anti-PD-(L)1 Immunotherapies in Chinese Patients with Advanced Non-Small Cell Lung Cancer

2018 · S. Zhao, Y. Jia, et al. · Journal of Thoracic Oncology · 2

PDF

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

2017 · S. Ren, G. Gao, et al. · Journal of Thoracic Oncology · 2

PDF

P3.01-085 A Phase 2 Trial of Apatinib in Advanced Non-Squamous NSCLC: Updated Data and Clinical Benefit of Continuing Apatinib after Initial Progression

2017 · F. Wu, S. Zhang, et al. · Journal of Thoracic Oncology · 2

Coexistence of Egfr Mutations with Alk, Ros1 or Ret Rearrangements in Lung Adenocarcinoma: a Clinicopathological Analysis from 646 Chinese Patients with Lung Adenocarcinoma

2014 · W. Cai, C. Zhou, et al. · Annals of Oncology · 2

MA26.05 Comprehensive Analysis of Treatment Response and Progression Pattern in Chinese Patients with Different ALK Fusion-Variants

2018 · M. Qiao, C. Zhao, et al. · Journal of Thoracic Oncology · 1

PDF

P1.03-052 Comparing EGFR-TKI with EGFR-TKI plus Chemotherapy as 1st Line Treatment in Advanced NSCLC Patients with Both Mutated EGFR and Bim Polymorphism

2017 · Y. He, C. Zhao, et al. · Journal of Thoracic Oncology · 1

P3.01-067 TP53 Mutations Could Involve in EGFR-TKI Primary Resistance in Advanced Non-Small Cell Lung Cancer

2017 · X. Li, C. Su, et al. · Journal of Thoracic Oncology · 1

Open Repair of a Post-traumatic Pseudo-aneurysm of the Common Carotid Artery that Presented with Carotid Sinus Syndrome: A Case Report

2011 · M. Lou, Q. Zhang, et al. · EJVES Extra · 1

PDF

Semaphorin 3G coordinates neurovascular repair by enhancing Schwann cell migration and axonal regeneration through Nrp2/PlexinA4 signaling

2026 · Yi Shi, Lishan Lin, et al. · Acta Pharmaceutica Sinica B

505P Safety and preliminary efficacy of a novel CDK2/4 inhibitor TYK-00540 in patients with advanced solid tumors: Results from a phase I dose-escalation study

2025 · Y. Meng, X. Han, et al. · Annals of Oncology

EP.08F.16 Re-Irradiation with Chemotherapy with/without Immunotherapy for In-Field Local Recurrence Among Lung Cancer Patients

2024 · S. Vannhong, M. Wang, et al. · Journal of Thoracic Oncology

Lightening and Growing Your Stromatolites: Draw and Dive into Nature

2024 · Yancheng Cao, Xinghui Chen, et al. · Lecture notes in computer science

1332P Prognostic value of baseline and dynamic change value of CTC in advanced NSCLC patients treated with immune checkpoint inhibitor-based therapy

2020 · G. Gao, J. Li, et al. · Annals of Oncology

PDF

P2.01-30 Hepatitis B Infection or Aminotransferase Increase Associate with Poor Outcome of Anti-PD-1 Monotherapy in Patients with Advanced NSCLC

2019 · Y. Liu, S. Mao, et al. · Journal of Thoracic Oncology

PDF

P2.04-58 The Correlation Between TMB and Clinical Factors in East Asian Lung Cancer Patients with No TKI-Related Driver Gene-Mutations

2019 · Y. He, X. Chen, et al. · Journal of Thoracic Oncology

PDF

P2.03-36 tTMB and bTMB in East Asian Lung Cancer Patients with No TKI-Related Driver Gene Mutations

2019 · Y. He, X. Chen, et al. · Journal of Thoracic Oncology

PDF

EP1.12-07 High Discrepancy of Chemotherapy Outcomes Between Patients with Peripheral and Central Small Cell Lung Cancer

2019 · S. Mao, Q. Liu, et al. · Journal of Thoracic Oncology

PDF

Works count: 30

Citation count: 59

H-index: 3

I10-index: 2